We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Tokyo-based Eisai, along with U.S.-based Eisai Medical Research, will initiate a Phase III clinical program for eritoran as a potential treatment for severe sepsis.
The first clinical trial of a biologic nanoparticle designed to give back to cancer patients the tumor-busting gene they have lost is expected to start in September at Georgetown University Medical Center.
NexMed has reported that an early study showed its topical nail fungus treatment left substantially less drug in the bloodstream than the leading oral medicine, potentially making it a safer therapy.